A Digital Cognitive Behavioural Therapy for Insomnia Intervention in Mild Cognitive Impairment and Mild Dementia
Key facts
- Who runs it
- University College Cork
- Where
- Ireland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 1 Jan 2025
- Ended
- 30 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Digital cognitive behavioural therapy for insomnia
- Record updated
- 23 January 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥50 years
- Sleep Condition Indicator Score ≤16/32
- Established Mild Cognitive Impairment (MCI) or mild dementia, diagnosed by a consultant physician specialised in cognitive disorders prior to enrolment in the study. Dementia will be defined using DSM-5 classification and staged according to the Reisberg FAST scale into early/mild stage (Stages 1-4). MCI will be defined using Petersen's criteria. To participate those with MCI/mild dementia must score:; ≥18 on the Mini-Mental State Examination (MMSE), and; ≥0.5-1.0 on the Clinical Dementia Rating (CDR) scale
- Internet access for the duration of the intervention (via computer/tablet/smartphone)
- Sufficient physical/sensory (visual/hearing) capacity to use the intervention, as judged by the clinician/investigator
- English-speaker (intervention only available in English)
- Community-dwellers (non-institutionalised)
Who cannot take part
- Receipt of a sleep-related cognitive behavioural therapy (CBT) intervention within the past six months
- Planned surgery or hospitalisation during the study that could interfere with participation
- A change in the following medication within the three months prior to enrolment:; Benzodiazepine and non-benzodiazepine hypnotic or anxiolytics agents; Cholinesterase inhibitors or Memantine; Antidepressants; Antipsychotics; Amphetamine derivatives; Decongestants (pseudoephedrine, phenylephrine, phenyl¬propanolamine); Narcotic analgesics; β-Blockers; Pulmonary medications (theophylline and albuterol); Melatonin
- Known history of an International Classification of Diseases (ICD) defined sleep disorder other than insomnia disorder
- MMSE score <18 at enrolment, to facilitate adherence and ensure recruitment of those with mild-stage disease
- Unstable depression/anxiety disorders or panic attacks (unstable will be defined as changes in antidepressant medications within the last 3 months, i.e. no start, stop or change in dose)
- Other relevant major neuropsychiatric disorders, including schizophrenia, psychosis, mania, bipolar affective disorder, epilepsy or seizure disorder
- Long-term physical or sensory impairment, pain or other medical condition which, in the opinion of the principal investigator, could impair participation for reasons other than cognitive impairment
- Medical conditions rendering the patient too unwell to continue to participate in the study in the opinion of the principal investigator
- Severe depression (defined as depression requiring hospitalisation in the past 12-months or visit to psychiatry outpatient clinic in the past 3 months)
- Ongoing substance or alcohol abuse
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to assess the feasibility of conducting a definitive randomised controlled trial that will determine the effectiveness of a digital cognitive behavioural therapy for insomnia intervention (Sleepio) in improving sleep, psychosocial health and cognitive performance in people with Mild Cognitive Impairment or mild dementia and co-morbid sleep disturbance.
The 2 groups in the trial
- Intervention GroupTreatment being tested
Participants allocated to the intervention group will be provided with access to Sleepio, a fully-automated digital cognitive behavioural therapy for insomnia programme designed to treat insomnia using a combination of evidence-based cognitive and behavioural techniques. Underlying algorithms organise the delivery of information, support, and advice in a manner tailored to each individual participant based on their responses to an initial sleep study questionnaire and subsequent sleep diary entries throughout the duration of the programme. The Sleepio programme consists of six sessions, each ranging from five-to twenty minutes in duration. After the first session, each subsequent session is 'unlocked' one week after delivery of the prior session. Accordingly, the programme can be completed within a six-week period. However, the average time taken to complete the programme is 9-10 weeks.
Treatment: Digital cognitive behavioural therapy for insomnia
- Control GroupNo study treatment, for comparison
Participants allocated to the control group will continue to receive 'treatment-as-usual' throughout the duration of the study period. They will be informed that they will be provided with access to the intervention at the end of the study period.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised Controlled Feasibility Study of a Digital Cognitive Behavioural Therapy for Insomnia Intervention in Mild Cognitive Impairment and Mild Dementia: The Randomised Evaluation of Sleep in Cognitive Impairment Trial
- Publications
- Randomised Evaluation of Sleep in Cognitive Impairment Trial (REST)-Protocol for a Feasibility Study of a Digital Cognitive Behavioural Therapy for Insomnia Intervention.International journal of environmental research and public health, 2026
- Record updated
- 23 January 2026